CTI BioPharma (CTIC) Receives Nasdaq Listing Extension
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
CTI BioPharma Corp. (Nasdaq: CTIC) announced that on September 20, 2016, the NASDAQ Listing Qualifications staff granted the Company an additional 180 calendar day period, or until March 20, 2017, to regain compliance with the Minimum Bid Price Rule. To do so, the bid price of the Company's common stock must close at or above $1.00 per share for a minimum of 10 consecutive trading days prior to that date.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CTI BioPharma (CTIC), Baxalta Terminate Pacritinib Licensing Agreement (SHPG)
- The New York Times Co. (NYT) Announces Acquisition of Two Product-Recommendation Service Companies
- Littelfuse (LFUS) Boosts Q3 Outlook
Create E-mail Alert Related CategoriesCorporate News
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!